Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.

ABSTRACT:

Background

Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We evaluate baseline characteristics as predictors of sustained response and remission in patients with ulcerative colitis receiving tofacitinib maintenance therapy.

Methods

Patients with clinical response following OCTAVE Induction 1 and 2 entered OCTAVE Sustain and were rerandomized to receive tofacitinib 5 or 10 mg twice daily or placebo. Baseline characteristics were stratified by week 52 efficacy endpoints (remission, sustained remission, clinical response, sustained clinical response). Associations between baseline characteristics and efficacy endpoints were evaluated using logistic regression analyses.

Results

Overall, 170 of 487 (34.9%) patients were in rem

SUBMITTER: Sandborn WJ 

PROVIDER: S-EPMC9434448 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature